Merrimack Discontinues Phase 2 SHERLOC Study Of MM-121 In Patients With NSCLC

(RTTNews) - Merrimack Pharmaceuticals, Inc. (MACK) announced the termination of the SHERLOC study, the company's randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive non-small cell lung cancer. The company said the the data demonstrated that the addition of MM-121 to docetaxel did not improve progression free survival over docetaxel alone in this patient population.

Based on the results, Merrimack is implementing a comprehensive review of its drug candidate pipeline, including assessing the impact of these results on the continued development of MM-121. Merrimack will provide an update on its pipeline and the results of its portfolio review on its third quarter 2018 financial results call on November 7, 2018.